相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL)
Patrick Ehm et al.
CELLULAR SIGNALLING (2022)
JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative neoplasm (MPN)
Madeleine Glueck et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2022)
Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia
Veronika Ecker et al.
NATURE COMMUNICATIONS (2021)
Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo
Guifang Du et al.
CELL DEATH & DISEASE (2020)
Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms
Ami B. Patel et al.
LEUKEMIA (2020)
Lineage-specific control of TFIIH by MITF determines transcriptional homeostasis and DNA repair
Marcos Seoane et al.
ONCOGENE (2019)
Nuclear accumulation of SHIP1 mutants derived from AML patients leads to increased proliferation of leukemic cells
Marcus M. Nalaskowski et al.
CELLULAR SIGNALLING (2018)
Fine-tuning of substrate preferences of the Src-family kinase Lck revealed through a high-throughput specificity screen
Neel H. Shah et al.
ELIFE (2018)
SHIP1, but not an AML-derived SHIP1 mutant, suppresses myeloid leukemia growth in a xenotransplantation mouse model
M. Taeger et al.
GENE THERAPY (2017)
The role of constitutive activation of FMS-related tyrosine kinase-3 and NRas/KRas mutational status in infants with KMT2A-rearranged acute lymphoblastic leukemia
Henning Fedders et al.
HAEMATOLOGICA (2017)
The role of constitutive activation of FMS-related tyrosine kinase-3 and NRas/KRas mutational status in infants with KMT2A-rearranged acute lymphoblastic leukemia
Henning Fedders et al.
HAEMATOLOGICA (2017)
Regulation of immune cell signaling by SHIP1: A phosphatase, scaffold protein, and potential therapeutic target
Samantha D. Pauls et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
Differential Lyn-dependence of the SHIP1-deficient mast cell phenotype
Susana M. Nunes de Miranda et al.
CELL COMMUNICATION AND SIGNALING (2016)
The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins
Andrew D. Rouillard et al.
DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION (2016)
Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia
Zhengshan Chen et al.
NATURE (2015)
The tumor suppressor SHIP1 colocalizes in nucleolar cavities with p53 and components of PML nuclear bodies
Patrick Ehm' et al.
NUCLEUS (2015)
The tumor suppressor SHIP1 colocalizes in nucleolar cavities with p53 and components of PML nuclear bodies
Patrick Ehm' et al.
NUCLEUS (2015)
NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia
D. Gerloff et al.
LEUKEMIA (2015)
Philadelphia Chromosome Positive Pre-T Cell Acute Lymphoblastic Leukemia: A Rare Case Report and Short Review
Shailendra Prasad Verrma et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2014)
Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia
Kathrin M. Bernt et al.
FRONTIERS IN ONCOLOGY (2014)
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
Kerstin Maria Kampa-Schittenhelm et al.
MOLECULAR CANCER (2013)
Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling while Specifically Inducing Apoptosis in FLT3-Activated Leukemia Cells
Ruwanthi N. Gunawardane et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
Development of a Highly Selective c-Src Kinase Inhibitor
Kristoffer R. Brandvold et al.
ACS CHEMICAL BIOLOGY (2012)
A toolkit for graded expression of green fluorescent protein fusion proteins in mammalian cells
Marcus M. Nalaskowski et al.
ANALYTICAL BIOCHEMISTRY (2012)
The SH2-domain of SHIP1 interacts with the SHIP1 C-terminus: Impact on SHIP1/Ig-α interaction
Oindrilla Mukherjee et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2012)
SRC is a signaling mediator in FLT3-ITD-but not in FLT3-TKD-positive AML
Hannes Leischner et al.
BLOOD (2012)
Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling
Helena Brauer et al.
CELLULAR SIGNALLING (2012)
Molecular genetics of B-precursor acute lymphoblastic leukemia
Charles G. Mullighan
JOURNAL OF CLINICAL INVESTIGATION (2012)
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment
Tiziana Grafone et al.
ONCOLOGY REVIEWS (2012)
Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
Ting-Lei Gu et al.
PLOS ONE (2011)
Tyrosine phosphorylation of SHIP promotes its proteasomal degradation
Jens Ruschmann et al.
EXPERIMENTAL HEMATOLOGY (2010)
Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases
Ana V. Miletic et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar et al.
BLOOD (2009)
Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein β are targeted by miR-155 in B cells of Eμ-MiR-155 transgenic mice
Stefan Costinean et al.
BLOOD (2009)
Onco-miR-155 targets SHIP1 to promote TNFα-dependent growth of B cell lymphomas
Irene M. Pedersen et al.
EMBO MOLECULAR MEDICINE (2009)
Reduced proliferation of CD34+ cells from patients with acute myeloid leukemia after gene transfer of INPP5D
A. Metzner et al.
GENE THERAPY (2009)
Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing
Tony C. T. Lo et al.
LEUKEMIA RESEARCH (2009)
Inositol phosphatase SHIP1 is a primary target of miR-155
Ryan M. O'Connell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Acute lymphoblastic leukaemia
Ching-Hon Pui et al.
LANCET (2008)
Src-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines
Jie Zhang et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic mice
S Costinean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
bcr-abl-positive T-cell acute lymphoblastic leukemia associated with parvovirus B19 infection
O Abla et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2006)
Positive and negative regulation of mast cell activation by Lyn via the FcεRI
WB Xiao et al.
JOURNAL OF IMMUNOLOGY (2005)
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia
RW Stam et al.
BLOOD (2005)
Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations
LJ Robinson et al.
EXPERIMENTAL HEMATOLOGY (2005)
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
YG Hu et al.
NATURE GENETICS (2004)
SHIP1 and Lyn kinase negatively regulate integrin αIIbβ3 signaling in platelets
MJ Maxwell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Src family kinases, key regulators of signal transduction
SJ Parsons et al.
ONCOGENE (2004)
The inositol 5′-phosphatase SHIP-1 and the Src kinase Lyn negatively regulate macrophage colony-stimulating factor-induced Akt activity
CP Baran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases
L Tatton et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification
SA Armstrong et al.
CANCER CELL (2003)
SHIP, SHIP2, and PTEN activities are regulated in vivo by modulation of their protein levels: SHIP is up-regulated in macrophages and mast cells by lipopolysaccharide
LM Sly et al.
EXPERIMENTAL HEMATOLOGY (2003)
BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia
S Salesse et al.
ONCOGENE (2002)
SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL
M Sattler et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
